Predictive Toxicology
Predictive Toxicology: Stem Cell Characterization Must Mature
March 17 by Pharma IQ
In this interview, Phillip Hewitt, Head of Early Investigative Toxicology at Merck KGaA analyzes new innovations in predictive toxicology
Global ADME – Toxicology Testing Market Update
December 15 by Pharma IQIssues with toxicity remain one of the key reasons why promising drug candidates fail to make it beyond the lab – at a cost to both the company and ultimately the patient. A number of industry f...
Reducing Safety-Related Drug Attrition- An Interview with Gareth Waldron
December 16 by Gerald ClarkeSafety-related drug attrition is obviously a huge problem in drug trials. How can companies work to reduce this? We spoke with Gareth Waldron Non-Clinical Safety Lead at Pfizer Neusentis about in vi...
Reducing Late-Stage Biologic Failure with Immune Assays- An Interview with Harald Kropshofer
November 27 by Gerald ClarkeThere have been some high profile cases of antibodies causing severe reactions, as well as posing a high risk to patients, these late stage failures are hugely costly. Is there a way to prevent or pre...
Will in vitro/in silico Methods Ever Replace in vivo Methods in Toxicology? - An Interview with Jorrit Hornberg
October 18 by Gerald ClarkeAhead of the Cell Based Assays Conference in December, Pharma IQ spoke with Jorrit Hornberg about the advances in vitro and in silico predictive toxicology and what this means for in vivo assays. He...
The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics
November 06 by Andrea CharlesIn this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in...
Top Tips for Cost Effective Integration of Predictive Toxicology
November 04 by Andrea CharlesWith budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition. B...
Predictive Toxicology Conferences: Which Predictive Toxicology Conference Should I Go to?
September 02 by Pharma IQAdvantages of Attending a Predictive Toxicology Conference Did you know that the average cost of developing a new drug is almost $1bn? Predictive toxicology helps to prevent late stage failures an...
Pharma IQ Predictive Toxicology Conference to Feature Industry Panel on Reducing Risks Associated with New Predictive Toxicology Technology
January 17 by Pharma IQ NewsPharma IQ, a division of IQPC, a leading organiser of conferences worldwide, announced today that the Drug Safety Executive Council (DSEC) will lead an expert panel, “Reducing Risks Asso...
Is Predictive Toxicology the Fast Track to Safe Drugs?
December 01 by Andrea CharlesUnexpected toxicity is the single biggest cause of pipeline attrition. Dr. Thomas Steger-Hartmann, Head of Investigational Toxicology at Bayer Healthcare, spoke to Andrea Charles from Pharma IQ, about...
Reducing Late-Stage Biologic Failure with Immune Assays
April 18 by Harald KropshoferDr. H. Kropshofer is Senior Personalized Healthcare Leader in the Pharmaceutical Division of F. Hoffmann-La Roche. He is located in the head quarter in Basel, Switzerland. He is globally accountable f...
Lundbeck's Jorrit Hornberg on the Latest Predictive Toxicology Developments
April 18 by Jorrit J. Hornberg, PhDJorrit Hornberg, Head of Section of In-vitro Studies in the Department of Exploratory Toxicology at Lundbeck, speaks to Andrea Charles from Pharma IQ, about the latest devlopments in predictive toxico...
